Trial Profile
A Placebo-controlled, Randomised, Double-blind, Crossover Study of the Efficacy of Ivabradine in the Management of Chronic Refractory Angina.
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 16 Jul 2019
Price :
$35
*
At a glance
- Drugs Ivabradine (Primary)
- Indications Angina pectoris
- Focus Therapeutic Use
- 11 Mar 2019 Status changed from recruiting to discontinued.
- 01 Mar 2011 New trial record